AR074438A1 - Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal - Google Patents
Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonalInfo
- Publication number
- AR074438A1 AR074438A1 ARP090104623A ARP090104623A AR074438A1 AR 074438 A1 AR074438 A1 AR 074438A1 AR P090104623 A ARP090104623 A AR P090104623A AR P090104623 A ARP090104623 A AR P090104623A AR 074438 A1 AR074438 A1 AR 074438A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- modulation
- antibody
- antibodies
- monoclonal antibody
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000005557 antagonist Substances 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 238000012217 deletion Methods 0.000 abstract 2
- 230000037430 deletion Effects 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- 238000007792 addition Methods 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000009897 systematic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente solicitud se refiere al campo del diseno de anticuerpos, y más en particular, a un proceso para la identificación sistemática de anticuerpos y/o la modulación de la actividad agonista/antagonista de anticuerpos. Más en particular, la solicitud se refiere a un método para mejorar la actividad antagonista de un anticuerpo monoclonal dirigido contra una molécula blanco específica, o de un fragmento funcional divalente o un derivado de dicho anticuerpo, donde dicho anticuerpo es capaz de inhibir una o más de las actividades biológicas de dicha molécula blanco; donde dicho proceso comprende una etapa de reconfiguración de la región de bisagra, que consiste en una modificación de la secuencia de aminoácidos de dicha región de bisagra mediante la deleción, la adición o la sustitución de por lo menos un aminoácido. La presente además se refiere a polipéptidos útiles para dicho método de modulación, y a los anticuerpos obtenidos. Reivindicación 11: El proceso de una de las reivindicaciones 1 a 10, donde dicha modificación consiste en por lo menos una deleción de un aminoácido seleccionado del aminoácido en la posición H1, H2, H3, H5, H6, H7, H8, H9, H11, H12 o H14.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2008/055664 WO2010064090A1 (en) | 2008-12-02 | 2008-12-02 | Process for the modulation of the antagonistic activity of a monoclonal antibody |
| US18440609P | 2009-06-05 | 2009-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074438A1 true AR074438A1 (es) | 2011-01-19 |
Family
ID=41668304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104623A AR074438A1 (es) | 2008-12-02 | 2009-12-01 | Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9676839B2 (es) |
| EP (2) | EP3048113A1 (es) |
| JP (1) | JP5832899B2 (es) |
| KR (2) | KR20110091519A (es) |
| CN (2) | CN102232086B (es) |
| AR (1) | AR074438A1 (es) |
| AU (1) | AU2009324145B2 (es) |
| BR (1) | BRPI0923228B1 (es) |
| CA (1) | CA2744065C (es) |
| DK (1) | DK2370464T3 (es) |
| ES (1) | ES2600254T3 (es) |
| GE (1) | GEP20135931B (es) |
| IL (1) | IL213272A (es) |
| MA (1) | MA32838B1 (es) |
| MX (1) | MX2011005569A (es) |
| NZ (1) | NZ592830A (es) |
| SA (1) | SA109300723B1 (es) |
| TN (1) | TN2011000253A1 (es) |
| TW (1) | TWI631341B (es) |
| WO (1) | WO2010063746A1 (es) |
| ZA (1) | ZA201103831B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| CN105177091A (zh) | 2006-03-31 | 2015-12-23 | 中外制药株式会社 | 用于纯化双特异性抗体的抗体修饰方法 |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| KR102339457B1 (ko) | 2007-09-26 | 2021-12-14 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| WO2010107109A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| EP3511342B1 (en) | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
| EP2708556B1 (en) | 2012-09-12 | 2018-11-07 | Samsung Electronics Co., Ltd | Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN105764922B (zh) | 2013-09-27 | 2020-07-17 | 中外制药株式会社 | 多肽异源多聚体的制备方法 |
| US9717715B2 (en) | 2013-11-15 | 2017-08-01 | Samsung Electronics Co., Ltd. | Method of combination therapy using an anti-C-Met antibody |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| EP3590967A1 (en) * | 2014-03-24 | 2020-01-08 | Cancer Research Technology Limited | Modified antibodies containing modified igg2 domains which elicit agonist properties and use thereof |
| EP3699198B1 (en) | 2014-11-17 | 2025-03-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
| DK3277725T3 (da) | 2015-03-30 | 2021-01-11 | Regeneron Pharma | Konstante tungkædeområder med reduceret binding til FC-gammareceptorer |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| CA3004288C (en) | 2015-12-28 | 2025-05-27 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION |
| WO2018081448A1 (en) * | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| US20210252068A1 (en) * | 2018-06-15 | 2021-08-19 | The Regents Of The University Of California | Fusion Fragment Chimeric Antigen Receptors and Uses Thereof |
| DK3844189T3 (da) | 2018-08-31 | 2025-02-24 | Regeneron Pharma | Doseringsstrategi, der mindsker cytokinfrigivelsessyndrom for CD3/CD20-bispecifikke antistoffer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0315457D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| DK1707627T3 (da) | 2003-12-25 | 2012-12-17 | Kyowa Hakko Kirin Co Ltd | Antagonistisk anti-CD40-antistofmutant. |
| JP5255435B2 (ja) * | 2005-04-26 | 2013-08-07 | メディミューン，エルエルシー | ヒンジドメイン操作による抗体エフェクター機能の調節 |
| RS54984B1 (sr) * | 2005-07-18 | 2016-11-30 | Amgen Inc | Humana anti-b7rp1 neutrališuća antitela |
| JP5457671B2 (ja) * | 2005-07-28 | 2014-04-02 | ノバルティス アーゲー | Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用 |
| US8048421B2 (en) * | 2006-03-23 | 2011-11-01 | Kyowa Hakko Kirin Co., Ltd. | Agonist antibody to human thrombopoietin receptor |
| CN103183738B (zh) | 2006-03-30 | 2014-08-06 | 诺瓦提斯公司 | c-Met抗体的组合物和使用方法 |
| US8545839B2 (en) * | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
-
2009
- 2009-12-01 AR ARP090104623A patent/AR074438A1/es not_active Application Discontinuation
- 2009-12-02 DK DK09768518.4T patent/DK2370464T3/en active
- 2009-12-02 WO PCT/EP2009/066205 patent/WO2010063746A1/en not_active Ceased
- 2009-12-02 AU AU2009324145A patent/AU2009324145B2/en active Active
- 2009-12-02 JP JP2011539010A patent/JP5832899B2/ja active Active
- 2009-12-02 BR BRPI0923228-1A patent/BRPI0923228B1/pt active IP Right Grant
- 2009-12-02 KR KR1020117011857A patent/KR20110091519A/ko not_active Ceased
- 2009-12-02 CN CN200980148318.1A patent/CN102232086B/zh active Active
- 2009-12-02 TW TW098141150A patent/TWI631341B/zh active
- 2009-12-02 ES ES09768518.4T patent/ES2600254T3/es active Active
- 2009-12-02 EP EP15198444.0A patent/EP3048113A1/en not_active Withdrawn
- 2009-12-02 EP EP09768518.4A patent/EP2370464B1/en active Active
- 2009-12-02 KR KR1020177004586A patent/KR101971806B1/ko active Active
- 2009-12-02 US US13/131,907 patent/US9676839B2/en active Active
- 2009-12-02 CN CN201610093436.9A patent/CN105820241A/zh not_active Withdrawn
- 2009-12-02 MX MX2011005569A patent/MX2011005569A/es active IP Right Grant
- 2009-12-02 NZ NZ592830A patent/NZ592830A/xx unknown
- 2009-12-02 GE GEAP200912280A patent/GEP20135931B/en unknown
- 2009-12-02 CA CA2744065A patent/CA2744065C/en active Active
- 2009-12-05 SA SA109300723A patent/SA109300723B1/ar unknown
-
2011
- 2011-05-17 TN TN2011000253A patent/TN2011000253A1/fr unknown
- 2011-05-25 ZA ZA2011/03831A patent/ZA201103831B/en unknown
- 2011-05-31 MA MA33899A patent/MA32838B1/fr unknown
- 2011-05-31 IL IL213272A patent/IL213272A/en active IP Right Grant
-
2012
- 2012-09-14 US US13/619,379 patent/US20130109839A1/en not_active Abandoned
-
2015
- 2015-02-25 US US14/631,301 patent/US20150239958A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074438A1 (es) | Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal | |
| CY1124802T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
| ES2689080T3 (es) | Anticuerpos que se unen a TL1A y sus usos | |
| CY1121208T1 (el) | Σκευασματα αντισωματος ναταλιζουμαμπης | |
| EA201100094A1 (ru) | Тиадиазолилоксифениламидины и их применение в качестве фунгицидов | |
| MX389288B (es) | Compuestos heterocíclicos útiles como inhibidores de proteína cinasa-1 dependiente de 3-fosfoinositido (pdk1). | |
| BRPI0615705A2 (pt) | processo para preparar um composto, e, composto | |
| AR077756A1 (es) | Anticuerpos especificos para bacterias gram-positivas | |
| MX348432B (es) | Epitopes. | |
| EA201100093A1 (ru) | Тиадиазолилоксифениламидины и применение их в качестве фунгицидов | |
| BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
| WO2009112245A9 (en) | Antibody against the csf-1 r | |
| EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
| CO6251325A2 (es) | Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) | |
| AR059809A1 (es) | Anticuerpos anti-5t4 y sus usos | |
| AR085138A1 (es) | VARIANTES DE Fc Y METODOS PARA SU PRODUCCION | |
| EA200970605A1 (ru) | Ингибиторы mapk/erk-киназ | |
| AR069130A1 (es) | Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento | |
| BR112014012275A2 (pt) | purificação de proteína com a utilização de tampão bis-tris | |
| DK1912673T3 (da) | Fremgangsmåde til at binde effektor-molekyler til proteiner | |
| UY30128A1 (es) | Procedimientos para tratar perdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb | |
| DE602006019595D1 (de) | Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors | |
| ATE540026T1 (de) | Hydroxyphenylsulfonsäureamide als antiapoptotische bcl-inhibitoren | |
| BR112022009688A2 (pt) | Processo para a síntese de (3-cloro-2-piridil)hidrazina | |
| EA200701867A1 (ru) | Хинолиноновые соединения в качестве агонистов рецептора 5-ht |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |